Intellia Therapeutics Inc buy BMO Capital Markets
Start price
10.01.25
/
50%
€10.22
Target price
10.01.26
€48.67
Performance (%)
-25.05%
Price
08:01
€7.66
Summary
This prediction is currently active. The prediction for Intellia Therapeutics Inc disappoints with a performance of -25.05%. This prediction currently runs until 10.01.26. The prediction end date can be changed by BMO_Capital_Markets at any time. BMO_Capital_Markets has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Intellia Therapeutics Inc | -4.303% | -4.303% |
| iShares Core DAX® | 0.795% | 1.458% |
| iShares Nasdaq 100 | -3.088% | -0.762% |
| iShares Nikkei 225® | -0.952% | -2.268% |
| iShares S&P 500 | -1.393% | 0.199% |
Comments by BMO_Capital_Markets for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at BMO Capital Markets from $70.00 to $50.00. They now have an "outperform" rating on the stock.
Ratings data for NTLA provided by MarketBeat
Stopped prediction by BMO_Capital_Markets for Intellia Therapeutics Inc
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€22.72
10.05.24
10.05.24
€64.98
10.05.25
10.05.25
-67.39%
11.05.25
11.05.25
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€22.58
10.11.23
10.11.23
€58.01
10.11.24
10.11.24
-30.16%
11.11.24
11.11.24
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€36.37
13.03.23
13.03.23
-
13.03.24
13.03.24
-27.88%
14.03.24
14.03.24